AR SB446

Adds definition of "metastatic cancer" as cancer that has spread from its primary site to surrounding tissues, lymph nodes, or other body parts

Prohibits insurance policies covering metastatic cancer treatment from requiring step therapy for FDA-approved drugs on their formulary unless the preferred drug is consistent with best practices based on FDA-approved indications, National Comprehensive Cancer Network Compendium indications, or evidence-based peer-reviewed medical literature

Applies the step therapy restriction to both prescription medication benefits under Arkansas Code § 23-79-147 and utilization review entities under the Prior Authorization Transparency Act (§ 23-99-1114)

Preserves existing limitations on coverage for non-FDA-approved drugs and drugs contraindicated for specific cancer types

Approved April 4, 2019